Search results
Showing 31 to 45 of 70 results for gemcitabine
Evidence-based recommendations on sacituzumab govetican (Trodelvy) for treating unresectable, triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.
Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.
Awaiting development Reference number: GID-TA11591 Expected publication date: TBC
Awaiting development Reference number: GID-TA11560 Expected publication date: TBC
Awaiting development Reference number: GID-TA11868 Expected publication date: TBC
Awaiting development Reference number: GID-TA11872 Expected publication date: TBC
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)
Evidence-based recommendations on erlotinib (Tarceva) for the maintenance treatment of non-small-cell lung cancer in adults.
Evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have an autologous stem cell transplant.
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.
PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502
Discontinued Reference number: GID-TA10402
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Discontinued Reference number: GID-TA10329
Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]
Discontinued Reference number: GID-TAG494
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.